Navigation Links
MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus

ROCKVILLE, Md., July 13 /PRNewswire/ -- MacroGenics, Inc. today announced the initiation of the PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, a humanized monoclonal antibody, for the treatment of individuals with suspected central nervous system infection due to West Nile Virus (WNV). MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, was awarded a $50 million contract in September 2006 from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to support the development of MGAWN1.

The PARADIGM trial is a randomized, double-blind, multicenter, placebo-controlled study that is designed to evaluate the safety and efficacy of MGAWN1 in patients greater than or equal to 18 years of age with signs and symptoms of acute West Nile Neuroinvasive Disease. Approximately 20 sites in North America will be utilized for the conduct of the PARADIGM trial. For more information on the PARADIGM trial, please see

MacroGenics also announced today the completion ofa Phase 1 study of MGAWN1 in healthy volunteers, with the last patient having completed treatment in late 2008. This randomized, double-blind, dose-escalation cohort study was designed to evaluate the safety, tolerability, and pharmacokinetics of a single infusion of MGAWN1 in healthy adults. The study demonstrated the drug to be safe and well tolerated at all doses tested.

"We are delighted with the initiation of the PARADIGM trial as well as the completion of the Phase 1 trial," stated Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "Currently, there are no approved treatments for individuals with severe West Nile Virus infection. These patients are hospitalized and receive supportive care. Therefore, a therapy that neutralizes the virus and could possibly reduce or prevent complications associated with West Nile Neuroinvasive Disease would represent a significant advancement for these patients."

About MGAWN1

MGAWN1 is a humanized monoclonal antibody that specifically recognizes the envelope (E) protein of WNV. MGAWN1 exhibits potent neutralizing and fusion-inhibitory activity against WNV in laboratory studies conducted in vitro and in vivo. MGAWN1 has a specific activity that is orders of magnitude higher than that of an intravenous immune globulin (IVIG) product when tested in laboratory studies.

About West Nile Virus

West Nile Virus has widespread prevalence throughout the U.S. and other parts of North America. Approximately 20% of humans infected with WNV experience West Nile Feverwith clinical symptoms that include fever, headache, body aches, skin rash and swollen lymph glands. In approximately 1% of human infections, WNV enters the brain and causes severe, life-threatening neuroinvasive disease in the form of encephalitis, meningitis or acute flaccid paralysis. West Nile Neuroinvasive Disease (WNND) is associated with significant morbidity, and long-term neurological effects are common among survivors.

Since 1999, there have been more than 28,000 cases of confirmed symptomatic WNV infection in the U.S., which include more than 11,000 WNND cases and more than 1,100 deaths. In 2008, 1,356 cases of WNV infection were reported to the Centers for Disease Control and Prevention (CDC) for the year with 44 of these cases resulting in death. WNV is now the most common cause of epidemic viral encephalitis in the U.S., and it will likely remain an important cause of neurological disease for the foreseeable future. Since 2002, more than 4,500 cases of clinical WNV infection have been reported in Canada. No effective therapy or vaccine is available for humans. For more information about WNV, including maps of WNV activity, please visit

About MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a fully-integrated set of capabilities in monoclonal antibody product development. The company's product development efforts leverage three proprietary technology platforms: (1) cancer stem-like cells; (2) Dual Affinity Re-Targeting (DART), which allows the company to incorporate multiple specificities within a single molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. These powerful sets of capabilities and technology platforms have enabled MacroGenics to build a proprietary pipeline of innovative product candidates. The company's lead program, teplizumab, is an anti-CD3 antibody being developed for the treatment of autoimmune diseases. In October 2007, MacroGenics and Eli Lilly announced a global strategic alliance to develop and commercialize teplizumab as well as other potential next-generation anti-CD3 molecules. For more information about MacroGenics, please visit

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

SOURCE MacroGenics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Paulo F. Costa Joins MacroGenics Board of Directors
2. MacroGenics Appoints New Vice President of Business Development
3. MacroGenics Raises $25M in Series D-2 Financing
4. MacroGenics Acquires Raven Biotechnologies
5. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
7. Mirixa Corporation Announces Key New Hires
8. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
9. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for Pharmaceutical Engineering ... premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place ... the largest number of attendees in more than a decade. , “The ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  Clintrax Global, Inc., a ... North Carolina , today announced that the company has set ... represented a 391% quarter on quarter growth posted for Q3 of ... and Mexico , with the establishment ... in December 2015. --> United Kingdom ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader SAP and ... to develop and pitch their BIG ideas to improve health and wellness in their ... votes to win the title of SAP's Teen Innovator, an all-expenses paid trip to ...
(Date:11/24/2015)... -- SHPG ) announced today that Jeff Poulton ... th Annual Healthcare Conference in New York City ... EST (1:30 p.m. GMT). --> SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ...
Breaking Biology Technology:
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
(Date:10/26/2015)... Oct. 26, 2015  Delta ID Inc., a company ... mobile and PC devices, announced its ActiveIRIS® technology powers ... NX F-02H launched by NTT DOCOMO, INC in ... the second smartphone to include iris recognition technology, after ... NX F-04G in May 2015, world,s first smartphone to ...
(Date:10/22/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software and ... 30, 2015.  --> --> ... decrease of 33% compared to $6.0 million in the same quarter ... $2.2 million, or $0.10 per diluted share, which compared to $2.6 ... year ago.  --> --> ...
Breaking Biology News(10 mins):